Binding of pramipexole to extrastriatal dopamine D2/D3 receptors in the human brain: A positron emission tomography study using 11C-FLB 457

23Citations
Citations of this article
28Readers
Mendeley users who have this article in their library.

Abstract

The purpose of this study was to determine the binding sites of pramipexole in extrastriatal dopaminergic regions because its antidepressive effects have been speculated to occur by activating the dopamine D2 receptor subfamily in extrastriatal areas. Dynamic positron emission tomography (PET) scanning using 11C-FLB 457 for quantification of D2/D3 receptor subtype was performed on 15 healthy volunteers. Each subject underwent two PET scans before and after receiving a single dose of pramipexole (0, 0.125, or 0.25 mg). The study demonstrated that pramipexole significantly binds to D2/D3 receptors in the prefrontal cortex, amygdala, and medial and lateral thalamus at a dose of 0.25 mg. These regions have been indicated to have some relation to depression and may be part of the target sites where pramipexole exerts its antidepressive effects. © 2011 Ishibashi et al.

Cite

CITATION STYLE

APA

Ishibashi, K., Ishii, K., Oda, K., Mizusawa, H., & Ishiwata, K. (2011). Binding of pramipexole to extrastriatal dopamine D2/D3 receptors in the human brain: A positron emission tomography study using 11C-FLB 457. PLoS ONE, 6(3). https://doi.org/10.1371/journal.pone.0017723

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free